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ervation of both types of information in the
hippocampal output may form the basis of its
key role in episodic memory (2, 34).
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Complete Replication of Hepatitis
C Virus in Cell Culture
Brett D. Lindenbach,1 Matthew J. Evans,1 Andrew J. Syder,1
Benno Wo¨lk,1 Timothy L. Tellinghuisen,1 Christopher C. Liu,2
Toshiaki Maruyama,3* Richard O. Hynes,2 Dennis R. Burton,3
Jane A. McKeating,1. Charles M. Rice1-
Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced
in cell culture, which has slowed research progress on this important human
pathogen. Here, we describe a full-length HCV genome that replicates and
produces virus particles that are infectious in cell culture (HCVcc). Replication of
HCVcc was robust, producing nearly 105 infectious units per milliliter within 48
hours. Virus particles were filterable and neutralized with a monoclonal anti-
body against the viral glycoprotein E2. Viral entry was dependent on cellular
expression of a putative HCV receptor, CD81. HCVcc replication was inhibited
by interferon-a and by several HCV-specific antiviral compounds, suggesting
that this in vitro system will aid in the search for improved antivirals.
HCV is a major cause of chronic liver disease,
with over 170 million persistently infected
individuals worldwide (1). HCV-associated
liver disease frequently progresses to cirrhosis,
which can lead to liver failure and hepato-
cellular carcinoma. Current drug therapies are
often poorly tolerated and effective in only a
fraction of patients; there is no vaccine for
HCV. A major obstacle to understanding the
virus life cycle and to developing improved
therapeutics is the inability to efficiently grow
HCV in cell culture.
HCV is an enveloped, positive-sense RNA
virus of the family Flaviviridae. Naturally
occurring variants of HCV are classified into
six major genotypes. The 9.6-kb genome
encodes one large polyprotein that is processed
by viral and cellular proteinases to produce the
virion structural proteins (core and glycopro-
teins E1 and E2) as well as nonstructural (NS)
proteins (p7 through NS5B) (Fig. 1A). Sub-
genomic RNA replicons have been adapted for
efficient RNA replication in the human hepa-
toma line Huh-7 and other cultured cells (2–5).
However, full-length genomes containing cell
culture–adaptive mutations do not produce
infectious virus particles in culture and are
severely attenuated in vivo (6–8). This led us
to hypothesize that mutations that enhance
RNA replication may have deleterious effects
on virion production. To test this idea, we used
a genotype 2a subgenomic replicon, SGR-
JFH1, that efficiently replicates in cell culture
without adaptive mutations (4). Full-length
chimeric genomes were constructed with the
use of the core-NS2 gene regions from the
infectious J6 (genotype 2a) and H77 (genotype
1a) virus strains (Fig. 1A). Both full-length
chimeras and the subgenomic RNA were
competent for RNA replication, as seen by
the accumulation of NS5A protein and viral
RNA 48 hours after RNA transfection into the
Huh-7.5 cell line (Fig. 1B). As expected, mu-
tation of the NS5B RNA polymerase active
site EGlyAspAsp to GlyAsnAsp (GND)^
destroyed the ability of FL-J6/JFH to replicate
(Fig. 1B). Within transfected cells, both full-
length genomes expressed core, E2, and NS5A
(Fig. 1C). As expected, SGR-JFH1 expressed
NS5A but not core or E2. While ,30% of
cells were productively transfected with FL-
J6/JFH, FL-H77/JFH, or SGR-JFH1 RNA
(Fig. 1B), 995% of FL-J6/JFH–transfected cells
were positive for NS5A by 96 hours (fig.
S1). This suggested that FL-J6/JFH spread
within the transfected cell cultures.
To test whether infectivity could be trans-
ferred to naBve cells, we clarified conditioned
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media from these cultures by centrifugation
(9), filtered the supernatants (0.2 mm), and
incubated them with naBve Huh-7.5 cells.
NS5A expression could be transferred by
the FL-J6/JFH–transfected culture media
but not by media from cells transfected
with FL-H77/JFH or SGR-JFH1 (Fig. 1B).
Interestingly, the amount of FL-J6/JFH RNA
released into the transfected cell culture media
exceeded that of the other RNAs by a factor of
9200, and only FL-J6/JFH produced an
extracellular form of core (Fig. 1C, lower
panel). Given that the infectivity of the
genotype 2a chimera is filterable and is
associated with the release of HCV RNA and
core protein, we refer to this cell culture–
produced virus as HCVcc. The ability of the
genotype 1a/2a chimera to replicate but not
spread suggests that interactions between the
structural and nonstructural gene products may
be important for HCVcc formation, as has
been observed for other members of this virus
family (10, 11).
Limiting dilution assays for NS5A expres-
sion in electroporated cells showed that 30.3 T
9.5% (n 0 6) of cells were productively
transfected with FL-J6/JFH, and of these,
55% produced infectivity that was detectable
upon transfer to naBve cells. Thus, FL-J6/JFH
RNA transcripts were highly infectious and
formation of HCVcc did not depend on the
emergence of rare variants. Limiting dilution
assays were also used to quantitate the amount
of HCVcc infectivity between samples as
median tissue culture infectious units per
milliliter (TCID
50
/ml). The TCID
50
is the
dilution that infects 50% of replicate cell
cultures (9). After an eclipse phase (Q9 hours),
FL-J6/JFH infectivity could be detected in the
media by 18 hours posttransfection, and it
continued to accumulate until 48 hours (Fig.
1D). Interestingly, FL-J6/JFH (H2476L),
which contained a weakly adaptive mutation
in NS5B (4), showed slightly delayed growth
kinetics but also peaked to similar levels by 48
hours. Viruses could be serially passaged,
infecting 50 to 90% of cells within 5 days
after two rounds of passage at a low multi-
plicity of infection (MOI) of 0.1 to 1.0 (Fig.
1E). The expression and subcellular localiza-
tion of core, E2, and NS5A within FL-J6/JFH–
infected cells was consistent with what was
previously seen in full-length and subgenomic
replicon-bearing cells Esupporting online ma-
terial (SOM) text^. Taken together, these
measurements show that HCVcc replication
is robust and occurs with kinetics similar to
those of other Flaviviridae.
A classic method in virus identification is
to neutralize the suspected virus with specific
antisera. As shown in Fig. 2A, an E2-specific
human monoclonal antibody neutralized
HCVcc infectivity in a dose-dependent man-
ner, whereas an isotype-matched control anti-
body had no effect on HCVcc titer. These
data affirm the viral nature of HCVcc infec-
tivity and show that E2 is essential for virus
entry.
HCV E2 has been shown to bind to the
cellular surface protein CD81 (12), which is
an essential coreceptor for the entry of HCV
glycoprotein-pseudotyped retroviruses (13–15).
We found that HCVcc infectivity could be
blocked with a soluble recombinant form of
the CD81 large extracellular loop (Fig. 2B).
Fig. 1. Production of infectious HCV in cell culture. (A) The structures of the HCV RNA genome,
the SGR-JFH1 replicon, and full-length chimeric genomes FL-J6/JFH and FL-H77/JFH. NCR,
noncoding region; C, core; yellow, J6; cyan, H77. (B) Huh-7.5 cells were electroporated with RNA
transcripts of the indicated genomes [or the RNA-polymerase defective mutant FL-J6/JFH(GND)]
48 hours before immunostaining for NS5A (brown, upper panel). Nuclei were counterstained with
hematoxylin (blue). Below is the relative amount of HCV RNA detected in each transfected cell
population at 48 hours by quantitative reverse transcription polymerase chain reaction (RT-PCR).
Naı¨ve Huh-7.5 cells were incubated for 48 hours with filtered, conditioned media from the
transfected cells and immunostained for NS5A expression (lower panel). (C) Western blot for HCV
core, E2, NS5A, or actin protein expression at 48 hours in RNA transfected Huh-7.5 cells. Below
each lane is the relative amount of HCV RNA and core detected in cell culture media by
quantitative RT-PCR and Western blot, respectively. ND, not determined. (D) The accumulation of
HCVcc infectivity after electroporation of FL-J6/JFH (blue) or FL-J6/JFH (H2476L) (purple) into 6 
105 cells/timepoint, assessed by a limiting dilution assay (mean T SEM; n 0 4). Dotted line, assay
sensitivity. (E) Cells were immunostained for NS5A 5 days after infection with serially passaged
virus. Scale bars, 100 mm.
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To further examine the role of CD81 in virus
entry we used HepG2 cells, which lack CD81
expression but are capable of supporting HCV
RNA replication (3). As seen in Fig. 2C,
normal HepG2 cells were not infected by
FL-J6/JFH, whereas CD81-expressing HepG2
cells were infected under the same conditions,
albeit with reduced efficiency (,850 times less
than Huh-7.5 cells). These data confirm that
interactions between E2 and CD81 are impor-
tant for HCV entry.
The physical nature of HCV particles has
been difficult to study in the absence of an
infectious culture system. In density gradients,
clinical isolates of HCV exhibit a broad
distribution and unusually low buoyant den-
sities Ereviewed in (16)^. These properties have
been partly explained by the interaction of
HCV with serum components such as immuno-
globulins and b-lipoproteins. We examined
the profiles of RNA and infectivity associated
with HCVcc particles by equilibrium centrifu-
gation in 10 to 40% iodixanol, an iso-osmotic
gradient material. A series of controls con-
firmed that this method accurately measured
the buoyant density of HCVcc (SOM text).
HCV RNA was broadly distributed through
the top of the gradient, with a peak in fractions
16 and 17 (1.13 to 1.14 g/ml), and was not
found beyond fraction 20 (1.18 g/ml) (Fig.
3A). HCVcc infectivity was also broadly
distributed among fractions 1 to 15 (1.01 to
1.12 g/ml), and infectivity was not seen
beyond fraction 18 (1.17 g/ml). Surprisingly,
fractions 16 and 17, which contained the
highest levels of HCV RNA, had little
infectivity associated with them. The specific
infectivity of a virus preparation relates the
amount of infectivity to the total number of
virus particles or genomes in the preparation.
Interestingly, a plot of HCVcc-specific infec-
tivity versus buoyant density indicates that the
most infectious material is at 1.09 to 1.10 g/ml
(Fig. 3B), which is similar to the peak of
infectivity (1.09 to 1.11 g/ml) previously seen
in chimpanzees (17). In contrast, RNA-
containing material with a buoyant density of
1.14 g/ml (fraction 17) had a low specific
infectivity, with ,300,000 RNA molecules per
infectious unit. Many groups have reported an
HCV RNA peak near this density (18–20),
although infectivity could not be assessed.
Fig. 3. Characterization of HCVcc particles. (A) The profiles of FL-J6/JFH (H2476L) RNA (open circles)
and infectivity (solid gray) are shown after isopycnic centrifugation in a 10 to 40% iodixanol
gradient. Closed circles indicate the buoyant density of each fraction. (B) The specific infectivity of
each fraction in panel (A) was calculated as the infectivity per RNA copy and plotted against the
buoyant density.
Fig. 4. Antiviral inhibi-
tion of HCVcc. (A)
Huh-7.5 cells were
incubated for 18 hours
with the indicated
doses of IFN before in-
fection with FL-J6/JFH
(H2476L) (MOI of 1.0).
The fraction of inhibi-
tion was calculated
from the levels of HCV
RNA at 48 hours post-
infection. The mean T
SEM (n 0 3), best-fit
curve (black), and 95%
confidence interval (gray
curves) are shown. (B to
E) After 8 hours inoc-
ulation with FL-J6/JFH
(H2476L) (MOI of 0.1),
Huh-7.5 cells were
washed and incubated
in media containing
0.1% dimethylsulfoxide, as a carrier control, with or
without the indicated doses of each anti-HCV compound.
The inhibition of RNA accumulation at 48 hours was
calculated as above. 2¶C-MeAd, 2¶C-methyladenosine.
Fig. 2. HCVcc infection is dependent on HCV
glycoprotein functions. (A) FL-J6/JFH (H2476L)
was pre-incubated for 1 hour at 37-C with the
indicated concentrations of recombinant hu-
man anti-E2 C1 (circles) or anti-dengue virus
NS1 (square) immunoglobulin G1 monoclonal
antibodies (mAb), then titered by limiting
dilution assay (mean T SEM; n 0 3). Assays
for both antibodies were conducted in parallel.
The dotted line indicates the titer of untreated
virus. (B) FL-J6/JFH (H2476L) was preincubated
with 12 mg/ml of a recombinant form of the
large extracellular loop (LEL) of CD81 and used
to infect naı¨ve cells. The levels of HCV RNA,
relative to an untreated control, were deter-
mined at 48 hours postinfection by quantita-
tive RT-PCR (mean T SEM; n 0 4). (C) HepG2 or
HepG2/CD81 cells were infected with FL-J6/JFH
for 48 hours before immunostaining for NS5A
expression. Scale bar, 100 mm.
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Thus, HCVcc exhibits physical properties
similar to those that have been previously
described for natural isolates of HCV.
There is an urgent need for improved HCV
drug therapies. The current standard treatment,
pegylated interferon-a (IFNa) and ribavirin,
leads to a sustained response in only ,50% of
genotype 1–infected patients. We examined
the ability of HCVcc replication to be inhibited
by IFNa and other antiviral compounds. Dose-
response experiments showed that IFNa in-
hibited HCVcc RNA accumulation in infected
cells with a median effective concentration
(EC
50
) of 1 international unit (IU)/ml (Fig.
4A). We also tested three HCV-specific in-
hibitors of the NS3 serine protease for their
effects on HCVcc infection. As seen in Fig.
4, B to D, BILN 2061 (21), SCH6 (22), and
PI-1 (23) all inhibited HCVcc RNA accumu-
lation in the submicromolar range. In addition,
a nucleoside analog inhibitor of the NS5B
RNA polymerase, 2¶C-methyladenosine (24),
was found to inhibit HCVcc replication in the
low nanomolar range (Fig. 4E). Thus, HCVcc
infection can be inhibited by IFNa and sev-
eral HCV-specific antiviral compounds. The
specificity of these latter compounds further
shows that HCVcc infection leads to au-
thentic replication in target cells and dem-
onstrates that this infectious system may be
useful for testing current and future anti-
viral compounds.
We describe a full-length genotype 2a
HCV genome that replicates and produces
virus particles that are infectious in cell culture.
This system lays a foundation for future in
vitro studies to examine new aspects of the
virus life cycle and to develop new drugs for
combating HCV.
Note added in proof: Full-length JFH-1
has also been recently reported to produce
infectious virus in cell culture (25–27), as has
a genotype 1b Com1/JFH-1 chimera (28),
albeit with lower efficiency and slower
growth kinetics than the system reported here.
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Genome-Scale Identification
of Nucleosome Positions
in S. cerevisiae
Guo-Cheng Yuan, Yuen-Jong Liu,* Michael F. Dion,
Michael D. Slack,. Lani F. Wu, Steven J. Altschuler, Oliver J. Rando-
The positioning of nucleosomes along chromatin has been implicated in the
regulation of gene expression in eukaryotic cells, because packaging DNA into
nucleosomes affects sequence accessibility. We developed a tiled microarray
approach to identify at high resolution the translational positions of 2278
nucleosomes over 482 kilobases of Saccharomyces cerevisiae DNA, including
almost all of chromosome III and 223 additional regulatory regions. The majority
of the nucleosomes identified were well-positioned. We found a stereotyped
chromatin organization at Pol II promoters consisting of a nucleosome-free
region È200 base pairs upstream of the start codon flanked on both sides by
positioned nucleosomes. The nucleosome-free sequences were evolutionarily
conserved and were enriched in poly-deoxyadenosine or poly-deoxythymidine
sequences. Most occupied transcription factor binding motifs were devoid of
nucleosomes, strongly suggesting that nucleosome positioning is a global
determinant of transcription factor access.
Nucleosomes prevent many DNA binding
proteins from approaching their sites (1–3),
whereas appropriately positioned nucleosomes
can bring distant DNA sequences into close
proximity to promote transcription (4). Current
understanding of the primary structure of chro-
matin and its effects on gene expression comes
from a handful of well-characterized loci (see
examples below). High-resolution measurements
of nucleosome positions over chromosome-scale
distances would enhance our understanding of
chromatin structure and function.
To measure nucleosome positions on a
genomic scale, we developed a DNA micro-
array method (5) to identify nucleosomal and
linker DNA sequences on the basis of suscep-
tibility of linker DNA to micrococcal nuclease
(fig. S1). Nucleosomal DNA was isolated,
labeled with Cy3 fluorescent dye (green), and
mixed with Cy5-labeled total genomic DNA
(red). This mixture was hybridized to micro-
arrays printed with overlapping 50-mer oligo-
nucleotide probes tiled every 20 base pairs
across chromosomal regions of interest (fig.
Bauer Center for Genomics Research, Harvard Univer-
sity, 7 Divinity Avenue, Cambridge, MA 02138, USA.
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